Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0261
-0.0039 (-13.00%)
Jul 31, 2026, 11:52 AM EST
Adaptimmune Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5.92 | - | 60.28 | 27.15 | 6.15 | |
Revenue Growth | - | - | 122.05% | 341.50% | 55.36% |
Gross Profit | 5.92 | - | 60.28 | 27.15 | 6.15 |
Selling, General & Admin | 35.62 | 66.69 | 75.67 | 63.39 | 57.31 |
Research & Development | 48 | 111.63 | 144.27 | 127.73 | 111.09 |
Total Operating Expenses | 83.61 | 178.32 | 219.94 | 191.11 | 168.4 |
Operating Income | -77.69 | -178.32 | -159.66 | -163.97 | -162.25 |
Interest Income | 2.17 | 6.6 | 5.96 | 1.54 | 1.1 |
Interest Expense | -7.27 | -6.57 | -2.12 | - | - |
Other Non-Operating Income (Expense) | 4.78 | -4.62 | 25.01 | -0.54 | 3.85 |
Total Non-Operating Income (Expense) | -0.32 | -4.6 | 28.85 | 1.01 | 4.95 |
Pretax Income | -78.01 | -182.92 | -130.81 | -162.96 | -157.3 |
Provision for Income Taxes | - | - | 13.73 | -2.5 | -0.79 |
Net Income | -78.01 | -182.92 | -144.54 | -160.46 | -156.51 |
Earnings From Discontinued Operations | 103.21 | 105 | - | - | - |
Net Income to Common | 25.21 | -77.92 | -144.54 | -165.46 | -158.09 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 1,577 | 1,514 | 1,206 | 967 | 935 |
Shares Outstanding (Diluted) | 1,634 | 1,766 | 1,206 | 967 | 935 |
Shares Change | -7.45% | 46.39% | 24.73% | 3.47% | 9.37% |
EPS (Basic) | 0.02 | -0.04 | -0.10 | -0.17 | -0.17 |
EPS (Diluted) | 0.02 | -0.04 | -0.10 | -0.17 | -0.17 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -122.3 | -70 | -141.95 | -171.27 | 5.12 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Per Share | -0.07 | -0.04 | -0.12 | -0.18 | 0.01 |
Gross Margin | 100.00% | - | 100.00% | 100.00% | 100.00% |
Operating Margin | -1311.39% | - | -264.86% | -603.97% | -2638.58% |
Profit Margin | -1316.78% | - | -239.77% | -591.06% | -2545.26% |
FCF Margin | -2064.40% | - | -235.49% | -630.86% | 83.20% |
EBITDA | -66.38 | -162.33 | -149.99 | -157.89 | -155.68 |
EBITDA Margin | -1120.59% | - | -248.81% | -581.59% | -2531.78% |
EBIT | -77.69 | -178.32 | -159.66 | -163.97 | -162.25 |
EBIT Margin | -1311.39% | - | -264.86% | -603.97% | -2638.58% |
Effective Tax Rate | 0.00% | 0.00% | -10.49% | 1.53% | 0.50% |